STOCK TITAN

[8-K] HCW Biologics Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

HCW Biologics (Nasdaq: HCWB) filed an 8-K announcing it has regained full compliance with Nasdaq Capital Market rules, including Listing Rule 5550(b)(1) on minimum shareholders’ equity. Earlier, on May 13, 2025, Nasdaq confirmed compliance with the bid-price, public-float and market-value requirements.

All prior delisting proceedings are now closed. However, HCWB will remain under a “Panel Monitor” until June 23, 2026. Any breach of the Equity Rule during this one-year period would trigger an immediate hearing without the usual compliance-plan option. No financial results were disclosed.

HCW Biologics (Nasdaq: HCWB) ha presentato un modulo 8-K annunciando di aver ritrovato la piena conformità alle regole del Nasdaq Capital Market, inclusa la Regola di Quotazione 5550(b)(1) riguardante il patrimonio netto minimo degli azionisti. In precedenza, il 13 maggio 2025, il Nasdaq aveva confermato la conformità ai requisiti relativi al prezzo di offerta, alla flottazione pubblica e al valore di mercato.

Tutte le procedure di delisting precedenti sono ora chiuse. Tuttavia, HCWB rimarrà sotto la supervisione di un “Panel Monitor” fino al 23 giugno 2026. Qualsiasi violazione della Regola sul Patrimonio Netto durante questo periodo di un anno comporterebbe un'udienza immediata senza la consueta possibilità di un piano di conformità. Non sono stati divulgati risultati finanziari.

HCW Biologics (Nasdaq: HCWB) presentó un formulario 8-K anunciando que ha recuperado el cumplimiento total con las normas del Nasdaq Capital Market, incluyendo la Regla de Listado 5550(b)(1) sobre el patrimonio mínimo de los accionistas. Anteriormente, el 13 de mayo de 2025, Nasdaq confirmó el cumplimiento con los requisitos de precio de oferta, flotación pública y valor de mercado.

Todos los procedimientos previos de deslistado están ahora cerrados. Sin embargo, HCWB permanecerá bajo un “Panel Monitor” hasta el 23 de junio de 2026. Cualquier incumplimiento de la Regla de Patrimonio durante este período de un año desencadenaría una audiencia inmediata sin la opción habitual de un plan de cumplimiento. No se divulgaron resultados financieros.

HCW Biologics (나스닥: HCWB)는 8-K 보고서를 제출하며 나스닥 자본시장 규정, 특히 최소 주주 자본 요건인 상장 규칙 5550(b)(1)를 완전히 준수하게 되었음을 발표했습니다. 앞서 2025년 5월 13일, 나스닥은 입찰가, 공개 유통 주식 수 및 시장 가치 요건 준수를 확인했습니다.

이전의 모든 상장폐지 절차는 이제 종료되었습니다. 그러나 HCWB는 2026년 6월 23일까지 “패널 모니터” 상태를 유지할 예정입니다. 이 1년 기간 동안 자본 규칙 위반 시, 일반적인 준수 계획 옵션 없이 즉각 청문회가 열릴 것입니다. 재무 결과는 공개되지 않았습니다.

HCW Biologics (Nasdaq : HCWB) a déposé un formulaire 8-K annonçant qu'elle a retrouvé une conformité totale avec les règles du Nasdaq Capital Market, y compris la règle de cotation 5550(b)(1) relative aux capitaux propres minimums des actionnaires. Plus tôt, le 13 mai 2025, le Nasdaq avait confirmé la conformité aux exigences concernant le prix d'offre, la flottation publique et la valeur de marché.

Toutes les procédures de radiation antérieures sont désormais clôturées. Cependant, HCWB restera sous la surveillance d’un « Panel Monitor » jusqu’au 23 juin 2026. Toute violation de la règle sur les capitaux propres durant cette période d’un an entraînerait une audience immédiate sans l’option habituelle d’un plan de conformité. Aucun résultat financier n’a été communiqué.

HCW Biologics (Nasdaq: HCWB) hat einen 8-K-Bericht eingereicht und bekannt gegeben, dass das Unternehmen die volle Einhaltung der Regeln des Nasdaq Capital Market, einschließlich der Listing-Regel 5550(b)(1) bezüglich des Mindestaktionärskapitals, wiedererlangt hat. Bereits am 13. Mai 2025 bestätigte Nasdaq die Einhaltung der Anforderungen an den Gebotspreis, den Streubesitz und den Marktwert.

Alle vorherigen Delisting-Verfahren sind nun abgeschlossen. HCWB bleibt jedoch bis zum 23. Juni 2026 unter der Aufsicht eines „Panel Monitor“. Ein Verstoß gegen die Kapitalregel während dieses einjährigen Zeitraums würde eine sofortige Anhörung ohne die übliche Möglichkeit eines Compliance-Plans auslösen. Finanzielle Ergebnisse wurden nicht bekannt gegeben.

Positive
  • Full Nasdaq listing compliance restored; prior delisting proceedings closed
Negative
  • Company subject to one-year Panel Monitor; any equity rule breach triggers immediate hearing without remediation period

Insights

TL;DR: Delisting threat lifted; monitoring adds mild overhang.

Nasdaq’s notice decisively removes the immediate risk of HCWB shares being kicked off the Capital Market tier, a key relief for both liquidity and valuation. Closing the compliance file signals improved capitalization and trading metrics, potentially restoring institutional confidence and widening the eligible investor base. The one-year Panel Monitor is standard but limits management’s margin for error; any equity shortfall now bypasses staff remediation and heads straight to a hearing, shortening the cure runway. Investors should watch quarterly balance-sheet levels to ensure equity stays above the threshold. Overall, governance risk declines, yet vigilance remains necessary.

TL;DR: Positive news tempered by conditional oversight.

The removal of delisting risk is a clear short-term positive, improving trading stability and reducing event-driven volatility. That said, the Panel Monitor introduces a binary downside catalyst: a single equity slip could fast-track a hearing with no automatic compliance plan, compressing response time. Given HCWB’s emerging-growth status, capital raises or market swings could still pressure shareholder equity. The balance of probabilities favors stability, but the monitoring clause keeps a modest risk premium in the stock.

HCW Biologics (Nasdaq: HCWB) ha presentato un modulo 8-K annunciando di aver ritrovato la piena conformità alle regole del Nasdaq Capital Market, inclusa la Regola di Quotazione 5550(b)(1) riguardante il patrimonio netto minimo degli azionisti. In precedenza, il 13 maggio 2025, il Nasdaq aveva confermato la conformità ai requisiti relativi al prezzo di offerta, alla flottazione pubblica e al valore di mercato.

Tutte le procedure di delisting precedenti sono ora chiuse. Tuttavia, HCWB rimarrà sotto la supervisione di un “Panel Monitor” fino al 23 giugno 2026. Qualsiasi violazione della Regola sul Patrimonio Netto durante questo periodo di un anno comporterebbe un'udienza immediata senza la consueta possibilità di un piano di conformità. Non sono stati divulgati risultati finanziari.

HCW Biologics (Nasdaq: HCWB) presentó un formulario 8-K anunciando que ha recuperado el cumplimiento total con las normas del Nasdaq Capital Market, incluyendo la Regla de Listado 5550(b)(1) sobre el patrimonio mínimo de los accionistas. Anteriormente, el 13 de mayo de 2025, Nasdaq confirmó el cumplimiento con los requisitos de precio de oferta, flotación pública y valor de mercado.

Todos los procedimientos previos de deslistado están ahora cerrados. Sin embargo, HCWB permanecerá bajo un “Panel Monitor” hasta el 23 de junio de 2026. Cualquier incumplimiento de la Regla de Patrimonio durante este período de un año desencadenaría una audiencia inmediata sin la opción habitual de un plan de cumplimiento. No se divulgaron resultados financieros.

HCW Biologics (나스닥: HCWB)는 8-K 보고서를 제출하며 나스닥 자본시장 규정, 특히 최소 주주 자본 요건인 상장 규칙 5550(b)(1)를 완전히 준수하게 되었음을 발표했습니다. 앞서 2025년 5월 13일, 나스닥은 입찰가, 공개 유통 주식 수 및 시장 가치 요건 준수를 확인했습니다.

이전의 모든 상장폐지 절차는 이제 종료되었습니다. 그러나 HCWB는 2026년 6월 23일까지 “패널 모니터” 상태를 유지할 예정입니다. 이 1년 기간 동안 자본 규칙 위반 시, 일반적인 준수 계획 옵션 없이 즉각 청문회가 열릴 것입니다. 재무 결과는 공개되지 않았습니다.

HCW Biologics (Nasdaq : HCWB) a déposé un formulaire 8-K annonçant qu'elle a retrouvé une conformité totale avec les règles du Nasdaq Capital Market, y compris la règle de cotation 5550(b)(1) relative aux capitaux propres minimums des actionnaires. Plus tôt, le 13 mai 2025, le Nasdaq avait confirmé la conformité aux exigences concernant le prix d'offre, la flottation publique et la valeur de marché.

Toutes les procédures de radiation antérieures sont désormais clôturées. Cependant, HCWB restera sous la surveillance d’un « Panel Monitor » jusqu’au 23 juin 2026. Toute violation de la règle sur les capitaux propres durant cette période d’un an entraînerait une audience immédiate sans l’option habituelle d’un plan de conformité. Aucun résultat financier n’a été communiqué.

HCW Biologics (Nasdaq: HCWB) hat einen 8-K-Bericht eingereicht und bekannt gegeben, dass das Unternehmen die volle Einhaltung der Regeln des Nasdaq Capital Market, einschließlich der Listing-Regel 5550(b)(1) bezüglich des Mindestaktionärskapitals, wiedererlangt hat. Bereits am 13. Mai 2025 bestätigte Nasdaq die Einhaltung der Anforderungen an den Gebotspreis, den Streubesitz und den Marktwert.

Alle vorherigen Delisting-Verfahren sind nun abgeschlossen. HCWB bleibt jedoch bis zum 23. Juni 2026 unter der Aufsicht eines „Panel Monitor“. Ein Verstoß gegen die Kapitalregel während dieses einjährigen Zeitraums würde eine sofortige Anhörung ohne die übliche Möglichkeit eines Compliance-Plans auslösen. Finanzielle Ergebnisse wurden nicht bekannt gegeben.

0001828673false00018286732025-06-262025-06-26

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

 

 

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40591

82-5024477

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2929 N. Commerce Parkway

 

Miramar, Florida

 

33025

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 842-2024

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

HCWB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

Nasdaq Continued Listing Requirements

 

On June 26, 2025, HCW Biologics Inc. (the “Company”) announced that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”). On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). As a result, the Company is in compliance with all applicable criteria for continued listing on the Nasdaq Capital Market tier, and the previously disclosed listing compliance matters have been closed.

 

The Company was also notified that it will remain subject to a “Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through June 23, 2026. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company’s listing on Nasdaq pending completion of the hearing process.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

Description

99.1

Press Release, dated June 26, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

HCW BIOLOGICS INC.

 

 

 

 

Date:

June 26, 2025

By:

 /s/ Hing C. Wong

 

 

 

Hing C. Wong, Founder and Chief Executive Officer

 


FAQ

Why did HCWB file an 8-K on June 26, 2025?

The company disclosed that Nasdaq confirmed its compliance with all Capital Market listing rules, ending prior delisting proceedings.

Is HCW Biologics now fully compliant with Nasdaq requirements?

Yes. Nasdaq validated compliance with Equity Rule 5550(b)(1) and previously confirmed bid-price, public-float and market-value criteria.

How long will HCWB remain under Nasdaq Panel Monitor oversight?

HCWB will be monitored until June 23, 2026, a one-year period from the notice date.

What happens if HCWB violates the equity rule during monitoring?

The company must request a hearing; it cannot submit a compliance plan, and delisting action is stayed only until the hearing concludes.

Which listing rules had HCWB previously regained on May 13, 2025?

Nasdaq confirmed compliance with the bid-price rule 5550(a)(2), public float rule 5550(a)(4), and market-value rule 5550(a)(5).
Hcw Biologics Inc.

NASDAQ:HCWB

HCWB Rankings

HCWB Latest News

HCWB Latest SEC Filings

HCWB Stock Data

9.71M
1.55M
44.41%
7.02%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIRAMAR